{"classes":[{"categories":[{"measurements":[{"comment":"Insufficient number of participants with events.","groupId":"OG000","lowerLimit":"3.1","upperLimit":"NA","value":"4.1"},{"groupId":"OG001","lowerLimit":"2.6","upperLimit":"10.9","value":"6.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"description":"Measure of clinical benefit, defined as the time from initial tumor response to documented tumor progression.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with a deleterious mutation in one of the following genes: BRCA1, BRCA2, PALB2, RAD51C, or RAD51D.","id":"OG000","title":"Rucaparib Cohort A"},{"description":"Participants with a deleterious mutation in one of the following genes: BRD1, BRIP1, FANCA, NBN, RAD51, or RAD51B.","id":"OG001","title":"Rucaparib Cohort B"}],"paramType":"MEDIAN","populationDescription":"Efficacy population - all participants evaluable for response by RECIST v1.1 (or modified RECIST v1.1/PCWG3 for mCRPC participants).","reportingStatus":"POSTED","timeFrame":"From first dose of study drug until disease progression (up to approximately 2 years)","title":"Duration of Response","type":"SECONDARY","unitOfMeasure":"month"}